Restrictive fluid therapy and high-dose vitamin C in sepsis
- PMID: 35915241
- PMCID: PMC9341155
- DOI: 10.1038/s41581-022-00609-5
Restrictive fluid therapy and high-dose vitamin C in sepsis
Abstract
Two recent randomized trials provide evidence to guide the management of sepsis. The CLASSIC trial reports that restrictive fluid therapy has no mortality benefit compared to a standard regimen in patients with septic shock, whereas the LOVIT trial reports that high-dose intravenous vitamin C might be harmful in patients with severe sepsis.
Conflict of interest statement
M.P.P. is conducting a trial of mega-dose vitamin C in septic shock. R.B. is coducting a trial of the physiological effect of mega-dose vitamin C in septic shock and holds intellecutal property for mega-dose vitamin C therapy in sepsis.
Comment on
-
Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit.N Engl J Med. 2022 Jun 23;386(25):2387-2398. doi: 10.1056/NEJMoa2200644. Epub 2022 Jun 15. N Engl J Med. 2022. PMID: 35704292 Clinical Trial.
-
Restriction of Intravenous Fluid in ICU Patients with Septic Shock.N Engl J Med. 2022 Jun 30;386(26):2459-2470. doi: 10.1056/NEJMoa2202707. Epub 2022 Jun 17. N Engl J Med. 2022. PMID: 35709019 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
